AstraZeneca and Merck's Lynparza shows survival benefit in early breast cancer
libre de droit/iStock via Getty Images


Additional results from a phase 3 trial demonstrated a statistically significant improvement in overall survival compared to placebo in patients taking AstraZeneca (NASDAQ:AZN) and Merck's (NYSE:MRK) Lynparza (olaparib).
Results showed that Lynparza reduced the risk of death by 32% versus placebo and improved the three-year survival rate to 92.8% compared to 89.1% for those on placebo.

The OlympiA study enrolled patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy.
Earlier in March, the U.S. FDA granted an additional indication for Lynparza in a type of early-stage breast cancer.